WAM
ANIK icon

Wakefield Asset Management’s Anika Therapeutics ANIK Stock Holding History

Wakefield Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,080
Closed -$471K – 158
2019
Q4 		$471K Buy
+9,080
New +$527K 0.2% 134

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wakefield Asset Management's ANIK Position: Q1 2020 in Review

Wakefield Asset Management sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 9,080 shares — an estimated $471K sold.

Wakefield Asset Management first reported a position in ANIK in Q4 2019 and held it in 1 quarter. The position peaked at $471K in Q4 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Wakefield Asset Management reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Wakefield Asset Management sold 9,080 Anika Therapeutics shares in Q1 2020, an estimated $471K.
  • Wakefield Asset Management first reported a position in Anika Therapeutics in Q4 2019 and held it in 1 quarter.
  • Wakefield Asset Management's Anika Therapeutics position peaked at $471K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Wakefield Asset Management's 13F filing for Q1 2020, filed 12 May 2020.